Orthopedic Implants Maker Zimmer Biomet Gains Analyst Upgrade Amid Promising Growth From New Products, Demographic Trends
Portfolio Pulse from Vandana Singh
Zimmer Biomet Holdings Inc. (NYSE: ZBH) received an upgrade from Argus Research due to promising growth from new products and favorable demographic trends. The company plans to launch over 40 new products in the next 24-36 months, including the ROSA robotic surgery system and a cementless knee implant. Argus upgraded ZBH from Hold to Buy with a price target of $150, citing attractive valuation and a strategy to grow EPS faster than revenue.
May 21, 2024 | 6:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zimmer Biomet Holdings Inc. (NYSE: ZBH) has been upgraded by Argus Research from Hold to Buy, with a price target of $150. The upgrade is driven by the launch of new products like the ROSA robotic surgery system and a cementless knee implant, as well as favorable demographic trends and a post-pandemic recovery in elective procedures.
The upgrade from Argus Research, along with the introduction of new products and favorable demographic trends, is likely to positively impact Zimmer Biomet's stock price in the short term. The price target of $150 suggests significant upside potential from the current price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100